We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+12.94%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.11B
AUM Growth
+$673M
(+20%)
Cap. Flow
-$283M
Cap. Flow
% of AUM
-6.89%
Top 10 Holdings %
Top 10 Hldgs %
37.55%
Holding
125
New
30
Increased
16
Reduced
24
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AFIB
Acutus Medical Inc
AFIB
|
+$132M |
| 2 |
CalciMedica
CALC
|
+$78.7M |
| 3 |
Nkarta
NKTX
|
+$71.3M |
| 4 |
Centene
CNC
|
+$58.5M |
| 5 |
OSH
Oak Street Health, Inc.
OSH
|
+$42.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schrodinger
SDGR
|
+$123M |
| 2 |
HOLX
Hologic
HOLX
|
+$62.2M |
| 3 |
McKesson
MCK
|
+$42.7M |
| 4 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$31.2M |
| 5 |
Pacira BioSciences
PCRX
|
+$27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.18% |
| 2 | Financials | 1.23% |
| 3 | Industrials | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DFHTU
26
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
| $35.7M | 0.87% |
+3,360,000
| New | +$35.4M |
|
27
Glaukos
GKOS
$8.92B
| $34.4M | 0.84% |
695,523
-178,477
| -20% | -$7.84M |
|
|
ISEE
28
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $32.5M | 0.79% |
5,767,409
| – | – |
|
|
INZY
29
DELISTED
Inozyme Pharma
INZY
| $30.2M | 0.74% |
+1,150,299
| New | +$28.6M |
|
|
GBIO
30
DELISTED
Generation Bio
GBIO
| $29.7M | 0.72% |
96,122
-22,500
| -19% | -$5.38M |
|
31
Kodiak Sciences
KOD
$2.64B
| $29.4M | 0.72% |
+497,000
| New | +$24.9M |
|
32
QuidelOrtho
QDEL
$1.15B
| $28.6M | 0.7% |
+130,521
| New | +$29.1M |
|
|
ORTX
33
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $28.6M | 0.7% |
694,942
-31,057
| -4% | -$1.61M |
|
34
Puma Biotechnology
PBYI
$410M
| $28.5M | 0.69% |
+2,826,327
| New | +$28.8M |
|
|
BDSI
35
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $28.5M | 0.69% |
7,635,750
+1,090,250
| +17% | +$4.64M |
|
36
Molina Healthcare
MOH
$10.4B
| $28M | 0.68% |
153,000
+32,755
| +27% | +$5.96M |
|
37
Editas Medicine
EDIT
$413M
| $27.7M | 0.68% |
988,841
-170,000
| -15% | -$5.54M |
|
38
Vericel Corp
VCEL
$2.33B
| $27.6M | 0.67% |
1,490,118
-1,567,043
| -51% | -$25.9M |
|
|
DCPH
39
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $27.1M | 0.66% |
528,585
+106,906
| +25% | +$5.24M |
|
40
Fate Therapeutics
FATE
$284M
| $26.7M | 0.65% |
668,067
-245,708
| -27% | -$8.58M |
|
41
eHealth
EHTH
$43.5M
| $26.3M | 0.64% |
+333,411
| New | +$27M |
|
42
OraSure Technologies
OSUR
$275M
| $26.3M | 0.64% |
+2,160,983
| New | +$29.5M |
|
|
HOLX
43
DELISTED
Hologic
HOLX
| $25.8M | 0.63% |
388,000
-982,186
| -72% | -$62.2M |
|
|
XENT
44
DELISTED
Intersect ENT, Inc
XENT
| $25.7M | 0.62% |
1,573,534
-1,003,345
| -39% | -$18.2M |
|
|
VIVO
45
DELISTED
Meridian Bioscience Inc
VIVO
| $25.6M | 0.62% |
1,508,398
-154,602
| -9% | -$3M |
|
|
ADVM
46
DELISTED
Adverum Biotechnologies
ADVM
| $24.8M | 0.6% |
240,444
+157,054
| +188% | +$23.5M |
|
|
TCRR
47
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $24.4M | 0.59% |
+1,200,000
| New | +$21.1M |
|
48
Black Diamond Therapeutics
BDTX
$99.7M
| $24.3M | 0.59% |
802,511
+266,510
| +50% | +$8.11M |
|
|
ACCD
49
DELISTED
Accolade Inc
ACCD
| $24.3M | 0.59% |
+624,001
| New | +$21.5M |
|
50
American Well
AMWL
$184M
| $23.4M | 0.57% |
+39,556
| New | +$20.9M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q3 2020 Portfolio in Review
As of Q3 2020, Deerfield Management held 125 positions worth $4.11B, up 20% from $3.43B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $283M in Q3 2020, closing 24 positions and reducing 24 holdings. Its most notable exit was Schrodinger, an estimated $123M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 66% a quarter earlier, followed by Financials and Industrials.
Against the trend, Deerfield Management opened a new position in Acutus Medical Inc worth $129M.
- Deerfield Management's largest Q3 2020 buy was Acutus Medical Inc: 4,341,799 shares worth $129M.
- Deerfield Management added most to Centene in Q3 2020, an estimated $58.5M increase.
- Deerfield Management's biggest Q3 2020 reduction was Hologic, cutting an estimated $62.2M.
- Deerfield Management fully exited Schrodinger in Q3 2020, selling an estimated $123M.
- Deerfield Management's ten largest holdings make up 38% of its $4.11B portfolio in Q3 2020.
- Deerfield Management opened 30 new positions and closed 24 in Q3 2020.
- Deerfield Management's portfolio value rose 20% quarter-over-quarter to $4.11B.
Based on Deerfield Management's 13F filing for Q3 2020, filed 16 Nov 2020.